scholarly article | Q13442814 |
P356 | DOI | 10.1200/JCO.2004.05.142 |
P698 | PubMed publication ID | 15570074 |
P2093 | author name string | Pablo E Verde | |
Andreas Erbersdobler | |||
Stefan B Hosch | |||
Wolfram T Knoefel | |||
Christoph A Klein | |||
Jakob R Izbicki | |||
Winfried Schraut | |||
Nikolas H Stoecklein | |||
Claus F Eisenberger | |||
Andreas M Luebke | |||
Matthias Peiper | |||
Peter Scheunemann | |||
Franziska Stern | |||
P433 | issue | 23 | |
P921 | main subject | pancreatic ductal adenocarcinoma | Q18555956 |
invasive ductal carcinoma | Q1671685 | ||
pancreatic ductal carcinoma | Q8263002 | ||
P304 | page(s) | 4737-4745 | |
P577 | publication date | 2004-12-01 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma | |
P478 | volume | 22 |
Q35886631 | Adjuvant and neoadjuvant treatment in pancreatic cancer |
Q83973971 | Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin |
Q91622958 | Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma |
Q33489063 | Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis |
Q35987242 | Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma |
Q36463216 | Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification |
Q21129230 | Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma |
Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
Q43455376 | HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma |
Q26824528 | Molecular landscape of pancreatic cancer: implications for current clinical trials |
Q37125627 | Pancreatic carcinogenesis |
Q36600002 | Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis |
Q90164554 | The Implication of Cytogenetic Alterations in Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm Identified by Fluorescence In Situ Hybridization and Their Potential Diagnostic Utility |
Q90682184 | The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA |
Q37969932 | The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma |
Q34494019 | The molecular targets for the diagnosis and treatment of pancreatic cancer |
Q35793641 | The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. |
Q54737674 | The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma. |
Q48141659 | The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies |
Q35811043 | Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells |
Search more.